headquartered in canton, massachusetts, organogenesis inc. is a global leader in regenerative medicine, offering a portfolio of bioactive and acellular biomaterials products in advanced wound care and surgical biologics, including orthopedics and spine. organogenesis’ versatile portfolio is designed to treat a variety of patients with repair and regenerative needs.
Company profile
Ticker
ORGO
Exchange
Website
CEO
Gary S. Gillheeney
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Avista Healthcare Public Acquisition Corp.
SEC CIK
Corporate docs
Subsidiaries
Organogenesis Inc. • Prime Merger Sub, LLC • Organogenesis Switzerland GmbH ...
ORGO stock data
Latest filings (excl ownership)
8-K
Organogenesis Announces Favorable Court Ruling Dismissing Securities Fraud Case
3 Apr 24
10-K
2023 FY
Annual report
29 Feb 24
8-K
Organogenesis Holdings Inc. Reports Fourth Quarter 2023 and Fiscal Year 2023 Financial Results; Introduces Fiscal Year 2024 Guidance
29 Feb 24
10-Q
2023 Q3
Quarterly report
9 Nov 23
8-K
Organogenesis Holdings Inc. Reports Third Quarter 2023 Financial Results
9 Nov 23
10-Q
2023 Q2
Quarterly report
9 Aug 23
8-K
Organogenesis Holdings Inc. Reports Second Quarter 2023 Financial Results; Withdraws Fiscal Year 2023 Guidance
9 Aug 23
8-K
Submission of Matters to a Vote of Security Holders
16 Jun 23
10-Q
2023 Q1
Quarterly report
10 May 23
8-K
Organogenesis Holdings Inc. Reports First Quarter 2023 Financial Results
10 May 23
Transcripts
ORGO
Earnings call transcript
2023 Q4
29 Feb 24
ORGO
Earnings call transcript
2023 Q3
9 Nov 23
ORGO
Earnings call transcript
2023 Q2
9 Aug 23
ORGO
Earnings call transcript
2023 Q1
10 May 23
ORGO
Earnings call transcript
2022 Q4
1 Mar 23
ORGO
Earnings call transcript
2022 Q3
10 Nov 22
ORGO
Earnings call transcript
2022 Q2
9 Aug 22
ORGO
Earnings call transcript
2022 Q1
11 May 22
ORGO
Earnings call transcript
2021 Q4
2 Mar 22
ORGO
Earnings call transcript
2021 Q3
10 Nov 21
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 98.83 mm | 98.83 mm | 98.83 mm | 98.83 mm | 98.83 mm | 98.83 mm |
Cash burn (monthly) | (no burn) | 766.33 k | (no burn) | (no burn) | (no burn) | (no burn) |
Cash used (since last report) | n/a | 5.29 mm | n/a | n/a | n/a | n/a |
Cash remaining | n/a | 93.53 mm | n/a | n/a | n/a | n/a |
Runway (months of cash) | n/a | 122.1 | n/a | n/a | n/a | n/a |
Institutional ownership, Q3 2023
53.2% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 105 |
Opened positions | 12 |
Closed positions | 23 |
Increased positions | 36 |
Reduced positions | 37 |
13F shares | Current |
---|---|
Total value | 154.89 bn |
Total shares | 70.15 mm |
Total puts | 29.30 k |
Total calls | 73.60 k |
Total put/call ratio | 0.4 |
Largest owners | Shares | Value |
---|---|---|
Soleus Capital Management | 12.30 mm | $39.10 bn |
Ades Alan A. | 10.76 mm | $99.76 mm |
Soleus Capital Master Fund | 7.36 mm | $0.00 |
MS Morgan Stanley | 6.94 mm | $22.07 bn |
BLK Blackrock | 4.95 mm | $15.73 bn |
Vanguard | 3.70 mm | $11.75 bn |
Acadian Asset Management | 2.59 mm | $8.23 mm |
Geode Capital Management | 1.63 mm | $5.19 bn |
Aqr Capital Management | 1.54 mm | $4.91 bn |
Millennium Management | 1.32 mm | $4.20 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
1 Apr 24 | Gillheeney Gary S. | Class A Common Stock | Payment of exercise | Dispose F | No | No | 2.8 | 10,113 | 28.32 k | 2,351,949 |
1 Apr 24 | Grow Brian | Class A Common Stock | Payment of exercise | Dispose F | No | No | 2.8 | 1,977 | 5.54 k | 520,809 |
1 Apr 24 | Montecalvo Antonio S. | Class A Common Stock | Payment of exercise | Dispose F | No | No | 2.8 | 1,752 | 4.91 k | 168,268 |
1 Apr 24 | Bilbo Patrick | Class A Common Stock | Payment of exercise | Dispose F | No | No | 2.8 | 2,497 | 6.99 k | 809,082 |
1 Apr 24 | Lori Freedman | Class A Common Stock | Payment of exercise | Dispose F | No | No | 2.8 | 1,974 | 5.53 k | 469,272 |
News
Why Caterpillar Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
25 Apr 24
12 Health Care Stocks Moving In Thursday's Intraday Session
25 Apr 24
Cantor Fitzgerald Reiterates Overweight on Organogenesis Hldgs, Maintains $5 Price Target
1 Mar 24
Earnings Scheduled For February 29, 2024
29 Feb 24
A Preview Of Organogenesis Hldgs's Earnings
28 Feb 24
Press releases
Organogenesis Holdings Inc. to Report First Quarter of Fiscal Year 2024 Financial Results on May 9, 2024
16 Apr 24
Organogenesis Announces Favorable Court Ruling Dismissing Securities Fraud Case
3 Apr 24
ORGANOGENESIS ALERT: Bragar Eagel & Squire, P.C. is Investigating Organogenesis Holdings, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
15 Feb 24
Organogenesis Holdings Inc. to Participate in the BTIG Snowbird MedTech, Digital Health, Life Science and Diagnostic Tools Conference
12 Feb 24
ORGANOGENESIS ALERT: Bragar Eagel & Squire, P.C. is Investigating Organogenesis Holdings, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
8 Feb 24